Pre-Market: HIMS (Hims & Hers NYSE) $16.27 on 18 Feb 2026: earnings in focus

In pre-market trading on 18 Feb 2026 HIMS stock sits at USD 16.27, down slightly from yesterday, as investors position ahead of Hims & Hers Health, Inc.’s earnings due 23 Feb 2026. The company will report results after the market close, and expectations center on recurring prescription growth and margin progress. Market metrics show a PE of 30.72 and EPS of 0.53, while the stock trades well below its 50-day average of USD 31.23 and 200-day average of USD 45.48. We review fundamentals, technicals, analyst sentiment, and a Meyka forecast before the print.

HIMS stock pre-market snapshot and key numbers

Pre-market the NYSE-listed Hims & Hers Health, Inc. (HIMS) is quoted at USD 16.27 with a session range yesterday of USD 15.80-16.92 and a market cap of USD 3,569,730,105.00. Volume yesterday was 20,132,113.00 versus an average volume of 20,626,365.00, showing normal liquidity for a biotech/telehealth name. One immediate red flag: the 52-week range is USD 15.63-72.98, highlighting sharp prior volatility and a steep drawdown from the high.

Earnings calendar and expectations for HIMS stock

Hims & Hers will report earnings after market close on 23 Feb 2026. Analysts expect revenue growth driven by recurring prescriptions and direct-to-consumer sales. The company last reported EPS 0.53 and the street shows a mixed upgrade/downgrade split of 5 buys, 12 holds, and 10 sells. Legal and competitive items, such as recent semaglutide litigation coverage, could influence guidance and gross margin disclosure ahead of the call. For context on recent coverage see Reuters and Investors Business Daily reporting source source.

Fundamentals and valuation for HIMS stock

HIMS shows improving profitability with a trailing net margin near 6.05% and revenue per share USD 9.77. Key ratios: price-to-sales 1.62, price-to-book 6.33, and debt-to-equity 1.92, signaling leverage above healthcare peers. Current ratio is 1.88, supporting near-term liquidity. The stock trades materially below moving averages, implying either a valuation discount or continued growth concerns. Investors should weigh a PE of 30.72 against recent revenue growth of 69.33% in FY 2024.

Technicals and trading setup for HIMS stock

Technicals show an oversold momentum profile: RSI 17.22 and MACD -4.32 vs signal -3.46. Volatility is elevated with ATR 2.12 and Bollinger bands wide (lower 13.62, middle 24.48, upper 35.34). On-chain volume indicators show negative on-balance volume, indicating distribution. Short-term traders face high downside risk, while longer-term investors may view the oversold reading as entry timing after positive earnings or guidance.

Meyka AI rates HIMS with a score out of 100 and forecast for HIMS stock

Meyka AI rates HIMS with a score out of 100: 76.28 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly USD 18.83, quarterly USD 40.89, and yearly USD 64.90 for HIMS stock. Compared with the current price USD 16.27, the model implies a monthly upside of 15.75%, a quarterly upside of 151.30%, and a yearly upside of 298.90%. Forecasts are model-based projections and not guarantees.

Risks and catalysts for HIMS stock

Primary catalysts: stronger recurring prescription growth, improved gross margins, and clearer guidance on legal exposures. Primary risks: regulatory or legal setbacks, continued margin pressure, high leverage, and sector rotation away from growth healthcare names. Watch the upcoming earnings release and any updated forward guidance for direct evidence of margin recovery or subscription churn improvements. Monitor trading volume and the 50-day average crossing for conviction moves.

Final Thoughts

HIMS stock opens pre-market at USD 16.27 on 18 Feb 2026 with earnings due 23 Feb 2026. The company presents a mix of improving profitability and elevated leverage: PE 30.72, debt-to-equity 1.92, and revenue growth of 69.33% in FY 2024. Technicals are deeply oversold, with RSI 17.22, offering a short-term mean-reversion case if management delivers encouraging guidance. Meyka AI’s forecast model projects USD 64.90 in one year, implying ~298.90% upside from today, though model forecasts are not guarantees. Our key takeaway: treat HIMS as a high-volatility, event-driven name ahead of earnings. Use position sizing and watch guidance, prescription KPIs, and cash flow metrics before increasing exposure. For quick access to intraday quotes and our real-time grade, see the Meyka HIMS page Meyka HIMS page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.